These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 21568628

  • 21. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
    Schennach-Wolff R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M.
    J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
    [Abstract] [Full Text] [Related]

  • 22. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ, Ayuso JL, Gutiérrez M, Guimon J, Herraiz ML, Chinchilla A, Ayuso JL, González Pinto A, Eguiluz I, Fernández A.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996 Dec; 24(4):165-72. PubMed ID: 8984849
    [Abstract] [Full Text] [Related]

  • 23. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC, Bravin S, Fabiano L, Vanni S, Boscati L, Invernizzi G.
    Encephale; 1995 Dec; 21(5):555-8. PubMed ID: 8529564
    [Abstract] [Full Text] [Related]

  • 24. One-year functional outcomes of naturalistically treated patients with schizophrenia.
    Spellmann I, Riedel M, Schennach R, Seemüller F, Obermeier M, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ.
    Psychiatry Res; 2012 Aug 15; 198(3):378-85. PubMed ID: 22421065
    [Abstract] [Full Text] [Related]

  • 25. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
    Glick ID, Lemmens P, Vester-Blokland E.
    Int Clin Psychopharmacol; 2001 Sep 15; 16(5):265-74. PubMed ID: 11552769
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
    Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE.
    Am J Psychiatry; 2003 Aug 15; 160(8):1405-12. PubMed ID: 12900301
    [Abstract] [Full Text] [Related]

  • 28. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ, German Study Group on First-Episode Schizophrenia.
    J Clin Psychiatry; 2007 Nov 15; 68(11):1763-74. PubMed ID: 18052570
    [Abstract] [Full Text] [Related]

  • 29. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO.
    Int J Neuropsychopharmacol; 2009 Oct 15; 12(9):1233-48. PubMed ID: 19419595
    [Abstract] [Full Text] [Related]

  • 30. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
    Docherty JP, Baker RA, Eudicone J, Mathew S, Marcus RN, McQuade RD, Mankoski R.
    Schizophr Res; 2010 Jul 15; 120(1-3):199-203. PubMed ID: 20547037
    [Abstract] [Full Text] [Related]

  • 31. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
    Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC.
    Int Clin Psychopharmacol; 2001 Nov 15; 16(6):325-30. PubMed ID: 11712620
    [Abstract] [Full Text] [Related]

  • 32. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
    Peuskens J, Möller HJ, Puech A.
    Eur Neuropsychopharmacol; 2002 Aug 15; 12(4):305-10. PubMed ID: 12126869
    [Abstract] [Full Text] [Related]

  • 33. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U.
    Schizophr Res; 2012 Nov 15; 141(2-3):144-52. PubMed ID: 22954754
    [Abstract] [Full Text] [Related]

  • 34. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
    Rabinowitz J, Hornik T, Davidson M.
    J Clin Psychiatry; 2001 May 15; 62(5):343-6. PubMed ID: 11411815
    [Abstract] [Full Text] [Related]

  • 35. Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.
    Oosthuizen P, Emsley RA, Roberts MC, Turner J, Keyter L, Keyter N, Torreman M.
    Schizophr Res; 2002 Dec 01; 58(2-3):247-52. PubMed ID: 12409165
    [Abstract] [Full Text] [Related]

  • 36. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
    Janicak PG, Keck PE, Davis JM, Kasckow JW, Tugrul K, Dowd SM, Strong J, Sharma RP, Strakowski SM.
    J Clin Psychopharmacol; 2001 Aug 01; 21(4):360-8. PubMed ID: 11476119
    [Abstract] [Full Text] [Related]

  • 37. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
    Marder SR, Davis JM, Chouinard G.
    J Clin Psychiatry; 1997 Dec 01; 58(12):538-46. PubMed ID: 9448657
    [Abstract] [Full Text] [Related]

  • 38. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.
    Liu SK, Chen WJ, Chang CJ, Lin HN.
    Neuropsychopharmacology; 2000 Mar 01; 22(3):311-9. PubMed ID: 10693159
    [Abstract] [Full Text] [Related]

  • 39. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
    Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S.
    J Psychiatr Res; 2014 Dec 01; 59():125-31. PubMed ID: 25227564
    [Abstract] [Full Text] [Related]

  • 40. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
    Blin O, Azorin JM, Bouhours P.
    J Clin Psychopharmacol; 1996 Feb 01; 16(1):38-44. PubMed ID: 8834417
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.